Chiesi: EMA validates Chiesi and Protalix's dose variation for Fabry disease
The EMA has validated Chiesi Global Rare Diseases and Protalix's submission to update the dosing regimen of pegunigalsidase alfa.
Read full article »
Chiesi is an Italy-based pharmaceutical company that develops and commercializes novel therapeutics for the treatment of respiratory and rare diseases.
Read more